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Abstract 
Less developed countries (LDCs) are struggling with an increasing burden of breast cancer. It is important to identify 
what interventions might be most effective and feasible in reducing overall breast cancer mortality in a resource con-
strained settings. Mammography screening (MS) utilized in developed countries cannot be equally applied to LDCs. 
We provide a summary of the status of existing and past MS program attempts in LDCs, and try to determine the pre-
requisites under which any developing country is ready to benefit from a MS program. We make the case for a “mixed” 
portfolio of tools to reduce breast cancer mortality with MS reserved only for those sub-populations that meet the 
criteria. We hope our review will provide a background for policy makers to apply rigorous criteria before attempting 
to implement costly MS program and before judiciously evaluating additional competed programs in their countries.
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Background
Since 2008, breast cancer incidence has increased by 
more than 20  % and mortality has risen by 14  % (The 
International Agency for Research on Cancer (IARC) 
2013). In 2012 1.67 million new cancer cases and 0.52 
million cancer-related deaths were reported (Ferlay 
et al. 2013). Of these, 52.9 % of global cases and 62.1 % 
of breast cancer deaths occurred in less developed coun-
tries (LDCs) (CIA-The World Factbook 2014). Breast 
cancer mortality-to incidence (M/I) ratio for less devel-
oped regions is 0.37, compared with 0.20 for more devel-
oped regions (Ferlay et  al. 2013). Health ministries and 
health-care systems in LDCs are struggling to respond 
to the increasing morbidity and mortality from advanced 
cancers among patients treated in the public system and 
among the urban poor, rural, remote and indigenous 
populations (Goss et  al. 2013). Several studies have 
described the current status and challenges of breast 
cancer facing a number of key LDCs including Brazil, 
(Lee et  al. 2012) Mexico (Chavarri-Guerra et  al. 2012) 
and China (Fan et  al. 2014). For all of these countries, 
mortality is much higher due to low cancer awareness, 
lack of early detection with concomitant higher stage of 
disease at presentation, lack of an implemented, effective 
national screening program and lack of timely access to 
optimal cancer care, all of which challenges the ability of 
these LDCs to ameliorate their cancer burden.
Stated by the International Agency for Research on 
Cancer (IARC) that “an urgent need in cancer control 
today is to develop effective and affordable approaches 
to the early detection, diagnosis, and treatment of breast 
cancer among women living in LDCs” (The International 
Agency for Research on Cancer (IARC) 2013). Patients 
with late stage breast cancer associated with more sub-
stantial economic burden even in developed countries 
(DCs), (Remak and Brazil 2004) we believe developing an 
effective and affordable early detection approach may be 
the first step for majority LDCs.
An effective mammographic screening (MS) pro-
gram is considered the best tool available for early 
stage detection of breast cancer and can potentially 
reduce the risk of death from breast cancer (Wubker 
2013; Apesteguia Ciriza and Pina Insausti 2013). How-
ever, it has not been without controversy, views of the 
possible risk:benefit of MS are sharply polarized and 
increasingly vocal (Marmot 2013). In 2002, the IARC 
thoroughly reassessed evidence on the effectiveness 
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of MS with a goal of interpreting effectiveness and to 
attempt to balance expected risk:benefit ratios in spe-
cific target populations, aim to formulate recommen-
dations for further research and public health action 
(The International Agency for Research on Cancer 
(IARC) 2002). Until now the debate has still not been 
resolved. Some countries such as the United States 
(US) (US Preventive Services Task Force 2009) and 
Canada (Tonelli et al. 2011) have modified or updated 
their recommendation for MS programs timely. Like-
wise the United Kingdom (UK), has recently convened 
an independent panel to review the evidence (Marmot 
et al. 2012). It is apparent that universal standards for 
the implementation of MS programs in different coun-
tries, and within a specific country is not feasible, due 
to enormous variations in the population and availa-
bility of resources, and differing interpretations of the 
existing data. This has led to a wide diversity of recom-
mended guidelines (Table 1).
Whether MS programs should be implemented or not 
for the goal of down-staging and reduce mortality of 
breast cancer in LDCs is challenging the notion. Based 
on their current resource-limited health-care systems, 
most LDCs believe that “raising breast awareness may be 
a priority goal, before trying to implement wide spread 
population-based screening” (Harford 2011). However 
many LDCs are undergoing significant economic growth 
and change and have rapidly changing socioeconomic, 
infrastructure and ethnic changes occurring. It is thus an 
increasing challenge for all LDCs to gain an understand-
ing of the specific circumstances and criteria in which 
they would consider launching a MS program. Herein we 
provide a summary of the status of existing and past MS 
program attempts in LDCs and try to provide criteria on 
which this decision can be based.
Methods: search strategy and selection criteria
Medline (OVID), Pubmed and Web of Knowledge data-
bases were searched for the subject headings: “breast 
neoplasm,” “breast cancer,” “breast,” and “screening” 
both as single headings and combined, up to Decem-
ber 2013. Reference lists from relevant individual arti-
cles were examined for additional relevant articles. Full 
papers and/or abstracts were reviewed and included to 
illustrate the current status of mammography screen-
ing in LDCs if: (1) Mammography screening and related 
topics were specifically the topic of the manuscript 
or emphasized within it; (2) breast cancer screening 
described in the article referred specifically to women 
living in LDCs (not including those who live in or immi-
grated to developed countries); (3) the article (abstract) 
was published in English between 2002 and Decem-
ber 2013 [literature published subsequent to the pub-
lished IARC Handbook (The International Agency 
for Research on Cancer (IARC) 2002) of breast cancer 
screening in 2002].
Table 1 Mammography screening programs in selected LDCs and DCs
LDCs less developed countries, DCs developed countries, ACS American Cancer Society 2003, ACR American College of Radiology 2013, ACOG The American College of 
Obstetricians and Gynecologists 2011, USPSTF US Preventive Services Task Force (2009)
Country Organizational level Year implemented (nationwide) Participation rate Interval (years) Screening age
LDCs
 Russia Khanty-Mansiysky autonomous Region-Yugra 2007 67.50 % 2 >40
 Brazil State of Sao Paulo 2003 56.70 % 2 40–69
 Mexico Mexico City 2005 50 % 2 40–69
 Uruguay Nationwide 2006 Mandatory 2 40–59
 Hungary Nationwide 2002 56.30 % 2 45–65
 Croatia Nationwide 2006 60 % 2 50–69
 Poland Nationwide 2007 40 % 2 50–69
DCs
 Sweden Nationwide 1986 (97) 81 % 1.5/2 40–74
 UK Nationwide 1988 (96) 76 % 3 50–64
 Canada Nationwide 1988 79 % 2/3 50–74
 US Nationwide 1991 83 % 1 ≥40
 US-ACS 1 ≥40
 US-ACR 1 ≥40
 US-ACOG 1 ≥40
 USPSTF 2 50–75
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Review
The current status of mammography screening in LDCs
Through a literature search, we retrieved 246 articles 
relevant to MS in 40 LDCs. We divided LDCs into four 
levels of readiness for MS program implementation 
according to the articles we retrieved, as shown in Fig. 1.
Level I: LDCs with evaluable MS programs, nationwide or 
localized region
Eight LDCs have published results from their nationwide 
or local MS programs (Fig.  1 shaded in blue). Table  1 
compares the relevant criteria used to base the MS pro-
gram on and the MS guidelines that were in place at the 
time of the programs. In Russia, (Zakharova 2013) Bra-
zil, (Barreto et al. 2012; Mauad et al. 2011) and Mexico, 
(Rodriguez-Cuevas et al. 2009) due to large populations 
and diverse health care systems, MS is delivered in 
selected localized regions of the countries only, rather 
than a national MS program. In contrast, Hungary, 
(Boncz et al. 2013) Croatia, (Stamenic and Strnad 2011) 
Macedonia (Gershan and Antevska-Grujoska 2011) and 
Poland (Matkowski and Szynglarewicz 2011) has allowed 
implementation of nationwide MS programs. Since 2006 
Uruguay has a unique mandatory screening program 
termed “the obligation for working women” (female 
employees must complete breast screening in order to 
obtain a “health card” that all workers must have (Arie 
2013). Recommended screening age in Russia, Brazil, 
Mexico, Uruguay and Hungary includes women from 
age 40 and above, whereas in Croatia and Poland, screen-
ing is initiated in women only from age 50. Based upon 
the available data most countries set an upper age of 
69 years, although in Brazil no upper age limit is defined. 
Screening is generally conducted biennially. Adherence 
rates vary considerably, it is noteworthy that all programs 
have adherence rates well below 70 %, a level that is con-
sidered necessary to confer a reduction in breast cancer 
mortality (WHO 2008).
Level II: countries which have conducted studies and/or 
trials to evaluate the accuracy or cost effectiveness of a MS 
program
Twelve countries have published pilot studies (Fig.  1 
shaded in green), consisting of several sequential MS 
within a specific relatively resource-rich area within their 
country. These studies have evaluated several impor-
tant metrics: overall breast cancer detection rates; early 
detection rates; difficulties in implementation; strategies 
to expand adherence rates and; cost analyses aimed at 
informing policy makers on the importance and feasibil-
ity of a nationwide organized MS program. One exam-
ple is a study from India which found CBE performed 
Fig. 1 Current Status of mammography screening in LDCs. (All developed countries are shaded in red). Level I refers to countries which have 
nationwide or localized mammography screening programs (shaded in blue: Russia, Brazil, Mexico, Uruguay, Hungary, Croatia, Poland and Macedo-
nia); Level II refers to countries which have trials or studies in particular populations for the evaluation of mammography screening accuracy or cost-
effectiveness (shaded in green: South Africa, China, India, Indonesia, Tunisia, Trinidad and Tobago, Bosnia and Herzegovina, Colombia, Ukraine, Saudi 
Arabia and Egypt); Level III refers to countries which have surveys or questionnaires on breast cancer screening awareness and access to mam-
mography (shaded in orange: Sudan, Nigeria, United Arab Emirates, Turkey, Jordan, Iran, Ghana, Pakistan, Bangladesh, Malaysia, Sri Lanka, Uganda, 
Lebanon, Senegal, Nepal, Philippines, Lithuania, Palestine, Yemen and Qatar); Level IV refers to countries with no data reported (shaded in white)
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annually from age 40 to 60 almost as effective as bien-
nial MS in terms of reduction of breast cancer mortality, 
while incurring only half the total cost of a MS program, 
(Okonkwo et  al. 2008) suggested that western MS pro-
grams may not be cost-effective in LDCs, especially in 
light of competing health care priorities and economic 
conditions.
Level III: countries with population‑based surveys or 
questionnaires on breast cancer screening awareness 
and access to opportunistic mammography
Twenty LDCs (Fig. 1 shaded in orange) have no published 
studies or trials of MS in their countries. However, pop-
ulation-based surveys of public breast cancer awareness 
and opportunistic MS have occasionally been conducted. 
Generally, women in these LDCs were shown to have low 
breast cancer awareness, and mammography utilization 
rates were very low. Only 18.75  % of female physicians 
and 17.24  % of female non-health care personnel had 
mammogram in Iran (Kadivar et  al. 2012). One survey 
in a very low resource area of South Africa reported that 
“no woman had ever had a mammogram” (Maree et  al. 
2013).
Level IV: countries with no MS data reported
The remaining LDCs (shaded in white) have not reported 
any study related to the use of MS.
We also found that varying recommendations and/
or guidelines related to mammography are frequently 
issued by governments in LDCs but with no involve-
ment of ministries of health and no plan for guaranteeing 
implementation or monitoring of quality control or com-
pliance. Up to now, opportunistic MS in some countries 
such as Brazil and Mexico do not have any information 
or databases to understand what has been really going 
on. Some countries have voiced the intent to launch pre-
ventative “screening mammography” programs, but in 
reality they frequently are referring to “diagnostic mam-
mogram programs”, frequently involving a mammogram 
either after an opportunistic mammogram has been read 
as suspicious or after women have experienced symp-
toms suspicious of breast cancer (National Breast Cancer 
Foundation 2014). Thus inappropriate attempts to imple-
ment such a program in a resource constrained country 
may lead to disappointing results and contentious use of 
health care budgets (Tiezzi 2013).
There are no existing methods to evaluate whether a 
LDC is qualified to have a MS program, Breast Health 
Global Initiative (BHGI) has proposed stratified guide-
lines for early detection in resource constrained countries 
and true MS programs be reserved for “enhanced” and 
“maximal” resourced countries (Anderson et  al. 2011; 
Yip et al. 2008). In this manuscript we summarize certain 
prerequisites which must be met for a LDC to consider 
launching a MS program with a view to reducing national 
breast cancer specific mortality.
Criteria required for implementation of a MS program 
in LDCs
Here we propose five steps to determine readiness for a 
MS program (Table 2) as followed:
Target population
The first step is defining an appropriate “target popula-
tion,” a group who will have substantial net benefit from 
MS (Quanstrum and Hayward 2010). Target populations 
differ both between and within countries mainly depend-
ing on: breast cancer burden and life expectancy; sensi-
tivity and specificity of mammography; socioeconomic 
and educational level.
Disease burden (breast cancer prevalence, incidence 
and mortality rates) and life expectancy MS can be suc-
cessful when there are a critical number of potential 
breast cancer patients in the prevalence pool. There is a 
correlation between a country’s GDP and its age-stand-
ardized breast-cancer incidence, (Harford 2011) inci-
dences of DCs are 2–4 times of incidences of LDCs (as 
shown in Table 3). However, the incidence has increased 
rapidly, especially in socioeconomic developed areas 
of LDCs. For example, the observed age-standardized 
Table 2 Criteria required for  implementation of  a mam-
mography screening program in LDCs
Target population Breast cancer prevalence, incidence and 
mortality rates
Life expectancy
Sensitivity and specificity to mammography
Socioeconomic and educational level
Resources Mammogram equipment (quantity and 
quality)
Trained personnel
Program methods Age of initiation (40 or 50)
End age (69 or >70)
Frequency (once every 1, 2, 3 years)
View (single or double)
Technique (digital or film)
Review method (1 or 2 radiologists)
Combine BSE and/or CBE
Combine other image




Cost-effectiveness analysis Methods of CEA
Crosswise and longitudinal comparison
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incidence rates in the eastern coastal urban areas of 
China are similar to those observed in Japan (Fan et  al. 
2014). Of note, MS itself may contribute to the excess 
incidence rate in DCs (Welch and Black 2010). In the 
US female population age 50 and older, the age adjusted 
incidence of invasive breast cancer was around 273.86 
(per 100,000 people) in 1975, which rapidly increased to 
almost 396.94 by 1999 (Howlader et  al. 2013; DeSantis 
et  al. 2014). Similar increases were also observed in the 
UK, Canada, Sweden and Norway, after MS implementa-
tion (Jorgensen and Gotzsche 2009). Hence, some areas 
in LDCs may already have enough potential patients and 
are qualified to have MS. Estimates for breast cancer inci-
dence can be obtained from Globocan 2012, however, 
most LDCs cannot provide details on age-specific breast 
cancer prevalence and incidence rates, posing a challenge 
to accurately identify the best screening age group.
No data explicit declared the minimum absolute mor-
tality from breast cancer needed to warrant a MS pro-
gram, however, the mortality rates of some LDCs are 
similar to those of DCs (Table  3). Female overall life 
expectancy is another parameter requiring consideration 
as low life expectancy results in fewer life years that can 
be saved via MS. For example, in Sudan the breast cancer 
mortality rate (15.2 per 100,000 people) is similar to that 
of the US (14.9) and Canada (13.9), however Sudanese 
female life expectancy is almost 20  years shorter. Thus 
even if Sudan has met the other qualifying prerequisites, 
the population as a whole would not benefit from MS.
Factors effecting sensitivity and specificity of MS
Mammographic sensitivity was 80 % among women with 
predominantly fatty breasts, and just 30 % in women with 
extremely dense breasts (Mandelson et  al. 2000). With 
age increases, breast density decreases and MS efficacy 
increases. MS reduces mortality by about 20–35  % in 
women aged 50–69 years, with less reduction in women 
aged 40–49 years, (Elmore et al. 2005) and increased false 
positive in younger women with high density (Salas et al. 
2011). Hence, target population with low breast density 
may benefit more from MS. Breast density may exist 
across racial groups, greater in Asian women and least in 
African women, rely on BMI, age at screening, diet and 
alcohol intake, (del Carmen et al. 2007; Voevodina et al. 
2013) differences in age-specific breast density and mam-
mographic sensitivity need to be considered when decid-
ing whether to initiate MS in any specific LDC.
Socioeconomic and educational level
Socioeconomic and educational levels and cancer aware-
ness all affect the feasibility and utility of MS programs. 
Women in the US and Canada with high incomes and 
education levels were more likely to receive MS, (Katz 
and Hofer 1994) and women of low socioeconomic sta-
tus show a low re-attendance screening rate according 
to the experience of Ontario Breast Screening Program 
(Tatla et al. 2003). Population in many LDCs is of insuf-
ficient socioeconomic status and low cancer awareness, 
which will make a screening program of insufficient util-
ity, (Goss et  al. 2014) such as the coverage rate of one 
regional MS program was shown to be is only about 
30  % in Russia (Zakharova et  al. 2011). Hence, health 
care systems must have medical record systems that fol-
low patients over time, and education center may help 
to increase re-screening rate. For example, through tele-
phone reminder and guidance, percentage of women had 
Table 3 Breast cancer burden and demographics of selected countries
Incidence and mortality rate are defined as the age-standardized incidence or mortality per 100,000 people per year. Incidence, mortality, Mortality-to-incidence (M/I) 
ratio and 5-year prevalence proportion were obtained from Globocan 2012. Population, population density and life expectancy at birth were obtained from the World 
Bank data from 2012 (The World Bank 2014b)










China 22.1 5.4 0.24 129 1,350,695,000 (48.2 %) 144 76
India 25.8 12.7 0.49 92.6 1,236,686,732 (48.3 %) 411 68
Brazil 59.5 14.3 0.24 317.8 198,656,019 (50.8 %) 23 77
Russian Federation 45.6 17.2 0.38 328.3 143,533,000 (53.8 %) 9 75
Egypt 49.5 19.3 0.39 222.5 80,721,874 (49.8 %) 80 73
Sudan 27.8 15.2 0.55 108.8 37,195,349 (49.8 %) 20 63
US 92.9 14.9 0.16 753.7 313,914,040 (50.8 %) 34 81
UK 95 17.1 0.18 755.1 63,227,526 (50.8 %) 259 83
Canada 79.8 13.9 0.17 666.8 34,880,491 (50.4 %) 4 83
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mammograms increased from 3.9 to 46.4  % in Turkey 
(Baysal and Gozum 2011).
Due to the points discussed above, simply applying the 
screening population taken from the existing guidelines 
from DCs will not be effective in LDCs. In LDCs, the 
average age of women with breast cancer is 10–20 years 
younger than women in the Western countries (Moore 
et al. 2003). Therefore, we suggest that women with the 
highest breast cancer incidence rate in socioeconomically 
well-developed areas of LDCs can attempt to be con-
sidered for the target population of a MS program. The 
potential size of the target population can be estimated 
with age distribution data.
Evaluation of mammography resources and requirements 
for a MS program
A minimum density of mammography machines 
is necessary in order to facilitate an efficient and 
accessible nationwide program. Most LDCs lack 
adequate health care infrastructure for their entire 
population, (Melnikow et  al. 2013) the ratio of mam-
mography equipments to physicians who perform 
CBE is close to 20  % in the US, but less than 0.25  % 
in India, (Sarvazyan et  al. 2008) and in 2010 Sudan 
had only nine mammogram machines (WHO 2010. 
Canada has a mammography machine density of 72 
per 1,000,000, while Mexico has a density of 37 per 
1,000,000 (Chavarri-Guerra et al. 2012). The distribu-
tion of equipment is irregular due to economical het-
erogeneity in LDCs. In Brazil, the distribution ranges 
from two mammography machines in the northern 
state of Roraima (population of 450,579 in 2010) to 335 
machines in the southeastern state of São Paulo (popu-
lation 41,262,199 in 2010) (Lee et  al. 2012). The dis-
tance the target population must travel and how long it 
takes to access MS may impact the adherence rate of a 
program. Whether mobile mammography, which may 
help women overcome the socioeconomic barriers to 
screening in US, such as lack of transportation, finan-
cial limitations or lack of medical insurance, (Carkaci 
et  al. 2013) can be applied in LDCs with low popula-
tion density need further investigation.
The quality and maintenance of mammography equip-
ment is also of importance, as an example 20 % of mam-
mography facilities in some areas of Brazil are out of use 
(Lee et al. 2012). Meanwhile, competency and continuous 
medical education of personnel working in a MS pro-
gram also needs attention. A scarcity of technicians and 
radiologists specialized in breast imaging in Mexico and 
in the majority of Latin American countries, (Rodriguez-
Cuevas et  al. 2009) may lead to a sub-optimized out-
comes of MS implementation in these resource limited 
LDCs.
Optimizing methods of MS program
How to optimize and form an “effective and affordable” 
method for the implementation of MS in LDCs is a big 
challenge.
Screening methods: age range, interval, direction, technique 
and review methods
Screening strategies differ in the existing and past MS 
programs (shown in Table  1). No evidence showed dif-
ferent methods led to different screening outcome in 
LDCs. Data from DCs demonstrate that screening ben-
efit is reduced in younger women, even with shorter 
intervals (Pace and Keating 2014). Hence, although some 
guidelines recommend initiating annually mammogra-
phy at age 40, (Smith et al. 2003; Henderson et al. 2003; 
American College of Obstetricians-Gynecologists 2011; 
Drukteinis et  al. 2013) the US Preventive Services Task 
Force (USPSTF) recommends against routine screening 
mammography in women aged 40–49 years, and biennial 
screening mammography for women between the ages 
of 50 and 74  years (US Preventive Services Task Force 
2009). For women over 50  years in UK, annual screen-
ing is predicted to have a relatively small effect on breast 
cancer mortality, with a relative risk of death at 0.95 com-
pared with a 3-year screening interval (United Kingdom 
Co-ordinating Committee on Cancer Research 2002). 
Single-view mammography was used in the Swedish 
Two-county and Stockholm trials, while two-view mam-
mography was used in the Malmo, Goteborg, Health 
Insurance Plan and Canadian trials, and in the first screen 
in Edinburgh, (The International Agency for Research 
on Cancer (IARC) 2002 two views were medically more 
effective and reduced recall rates, (Wald et al. 1995) while 
no significant difference found in the reduction in breast 
cancer mortality between one view or two views (Ker-
likowske et  al. 1995). No randomized controlled trials 
have compared digital or film mammography specifically, 
and although digital mammography is generally consid-
ered to be more effective it is more expensive (Melnikow 
et al. 2013). Double reading by two physicians increased 
the rate of cancer detection, (Dinnes et al. 2001) although 
using computer-aided detection with final diagnosis 
determined by one physician might be more cost-effec-
tive method (Sato et al. 2012).
Combining CBE/BSE (breast self exam) or other imaging 
technology
The evidence supporting the value of combining CBE 
and BSE as methods to reduce breast cancer mortality 
is limited and mostly inferential (Drukteinis et al. 2013). 
Canadian guidelines recommend against BSE and CBE; 
(Tonelli et  al. 2011) USPSTF recommends against BSE 
and cites insufficient evidence to recommend CBE; (US 
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Preventive Services Task Force 2009) and ACOG recom-
mends annual CBE to women >40  years and BSE only 
for high risk patients (American College of Obstetri-
cians-Gynecologists 2011). Ultrasound is an established 
adjunct to mammography in imaging evaluation, can be 
an option for additional screening in women at high risk, 
similarly in candidates for magnetic resonance imaging 
(Smith et al. 2003; Henderson et al. 2003). With routinely 
MS, CBE/BSE may not improve outcome, however, in 
LDCs, training of BSE by increasing cancer awareness, 
may also improve early detection. Limited evidence 
showed that women who had CBE were more likely to 
undergo MS in Malaysia, (Dahlui et al. 2012) and ultra-
sound combined with mammography may result in effec-
tive protection for Chinese women based on the younger 
age at tumor onset (Huang et al. 2001).
The best method is still inconclusive and data from 
studies performed in DCs should be considered pruden-
tially in the setting of LDCs. It is necessary to create an 
“individualized” MS method for LDCs depending on dif-
ferent populations and medical resources, learning from 
the experiences in DCs and making appropriate improve-
ments and modifications.
Screening outcome
Short term outcomes of MS implementation appear 
promising in LDCs, in Brazil patients with clinical stage 
0–1 disease increased from 50 to 70.8  %; (Silva et  al. 
2013). In Russia, the average cancer detection rate was 
2.5 per 1000 women screened, with a significant increase 
in breast cancer incidence and a significant trend of 
decreased breast-cancer-related mortality; (Zakharova 
et  al. 2011). In Hungary, percentage of women under-
going mammography increased from 27.4 to 61.0  % in 
2002–2003, and 56.3 % in 2004–2005 after the introduc-
tion of the nationwide program (Boncz et al. 2008).
Long term outcomes are still unclear in LDCs, such 
as the precise mortality reduction rate, the overdiagno-
sis rate and false positive rate. Based on the current evi-
dence from DC, they are still controversial (Jorgensen 
2013). Some studies show a “significant” mortality reduc-
tion benefit of as much as 28–65  %, (Berry et  al. 2005) 
while others show a “minimum” benefit of as little as 
15  % (Gotzsche and Jorgensen 2013). Improvement in 
systemic treatments also contributed to mortality reduc-
tion, as 30  % reduction in breast cancer mortality was 
observed after screening and adjuvant therapy, 10  % 
of this reduction is due to screening and 20 % is due to 
treatment (Berry 2013). Overdiagnosis refers to MS 
detected breast cancers that might never have progressed 
to become symptomatic during a woman’s lifetime (The 
International Agency for Research on Cancer (IARC) 
2002). SEER (Surveillance, Epidemiology, and End 
Results) incidence and mortality data showed increased 
cancer diagnosis with no obvious change in cancer mor-
tality, suggesting the existence of overdiagnosis (Welch 
and Black 2010). Based on varying assumptions and sta-
tistical methods, one study extracted incidence data from 
two randomized controlled trials and found a “minimum 
rate” to be around 1 %; (Duffy et al. 2005) while a review 
based on published trends on incidence in five DCs found 
a “substantial rate” of 52  % (Jorgensen and Gotzsche 
2009). Plausible estimates need appropriate adjustments 
for lead time bias and the pre-existing trend of increas-
ing incidence in the population, so an overdiagnosis 
rate range from 1 to 10  % is generally accepted (Puliti 
et al. 2012). False positive findings are another inevitable 
challenge, may result in subsequent unnecessary surgi-
cal intervention, as well as greater short-term and long-
term negative psychosocial consequences (Brodersen and 
Siersma 2013). Estimated false positive rate was 17 % for 
women undergoing 10 biennial screening tests in Europe, 
(Paci 2012) and about 61 % for 40- or 50-year-old women 
undergoing 10  years of annual mammography in US 
(Pace and Keating 2014).
There is no single gold standard for reaching an unbi-
ased and reliable estimate of these long term outcomes, 
largely depending on the characteristic of target popu-
lation and screening methods. Hence, we recommend 
small-scale MS trial should be conducted and followed 
up before the implementation of a nationwide program 
in LDCs.
Cost‑effectiveness analysis
All the parameters discussed above, including target pop-
ulation, screening resources, detail screening methods 
and evaluated outcome should be integrated into a CEA, 
which is the final key step to enable policy makers to put 
forward a medical practice (Weinstein and Stason 1977). 
Generally incremental cost effectiveness ratio (ICER) is 
accepted to estimate the expected cost of a MS to units 
such as per life year saved, per quality adjusted life year 
(QALY) saved, per disability adjusted life year (DALY) 
averted and so on (Laxminarayan et  al. 2006). Bien-
nial digital mammography beginning at age 50 resulted 
in an incremental cost per life year of US$17,050 in the 
US, (Melnikow et al. 2013) and once every 3 years begin-
ning at age 50 in the UK was associated with £20,800 
(US$34,784) per QALY gained (Pharoah et  al. 2013). 
These results cannot be directly applicable to LDCs, each 
CEA should be assessed on a country-by-country basis. 
There is no data shows exactly what amount of “incre-
mental cost” is acceptable for individual LDCs, definitely 
not as much as that identical to the £20,000–30,000 
per QALY established in the UK (National Institute for 
Health and Care Excellence 2014). Complex models 
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require many assumptions, usually estimated by extrapo-
lating data from clinical results, are highly susceptible to 
both error and introduction of bias, (Detsky and Laupa-
cis 2007) hampering CEA conducted in LDCs. Limited 
data demonstrated that biennial MS for women aged 
40–60 years in India resulted in a cost of around US$3468 
per life year gained, (Okonkwo et  al. 2008) and around 
US$6516 (R$13573.07) in Brazil, (Peregrino et  al. 2012) 
policy makers struggle with determining the net benefit 
and dare not to quickly implement such a program.
We suggest crosswise and longitudinal comparisons 
can be used to roughly estimate the practicality of MS 
in LDCs. In a crosswise comparison, for example, 1 year 
of adjuvant trastuzumab was determined to be a cost-
effective treatment option in early-stage breast cancer, 
with the ICER per QALY was around US$8000 in China, 
(Chen et  al. 2009) and US$18,970 in the US (Liberato 
et  al. 2007). Based on ICER results of trastuzumab, by 
comparing ICER of MS in the US with the result esti-
mated for MS in China, we can roughly estimate whether 
such a program is worthy to carry out in China. In a 
longitudinal comparison, we can use of the cost-effec-
tiveness (CE)/GDP per capita ratio, (Yoo et  al. 2013) as 
well as CE/yearly health expenditures per capita ratio, 
(van Ineveld et al. 1993) to balance the differences among 
countries. If the CE/GDP per capita ratio is greater than 
1, then MS can be deemed inefficient, as the cost per life 
year saved exceeds the per capita GDP. Of note, indi-
vidual cost-effectiveness ratios are estimated for a single 
program, not for a group of programs vying for a fixed 
budget (Detsky and Laupacis 2007). To maximize health 
outcomes from a limited budget, policy makers still face 
the challenge of prudentially and equitably allocating 
resources across a defined number of competing needs 
(Detsky and Naglie 1990).
According to this “five steps” model proposed here, we 
have tested MS in Shanghai cautiously, trying to meet 
all the criteria required for implementation. Shanghai is 
a prosperous urban city of China, with relatively better 
medical resources. Cancer registry was set up since 1970’, 
and “Shanghai Cancer Report” is published by Shanghai 
Center of Disease Control yearly, with detail information 
of age specific cancer incidence, mortality and preva-
lence. We selected women with highest incidence rate 
(age of 45–69 years old) as target population. Two-view 
film mammography with annual screening was used in a 
localized area in Shanghai. Sensitivity of MS was tested 
in different age group, 65.4  % in age 45–59  years and 
66.8  % in age 60–69  years (Mo et  al. 2013). With ade-
quate follow-up, long term outcome can be analyzed and 
CEA will be conducted in the near future. Then screen-
ing methods may necessarily be modified, combing with 
breast exam and/or ultrasound. Only when net benefit 
has been observed, we may implement such a program to 
all over Shanghai.
Discussion
LDCs have experienced a marked increase in breast 
cancer burden, (Ferlay et  al. 2013) with poor cancer 
awareness of the public, delayed diagnosis, and non-
optimal and untimely treatment. Efforts are needed 
to improve patient outcomes (Goss et  al. 2014). Most 
LDCs prioritize early detection of breast cancer, and 
some may be eager to achieve this through MS pro-
grams. The aim of this review is to illustrate the status 
of existing and past MS program attempts in LDCs and 
outline the challenge and limitations of MS in these 
countries.
There are some limitations to this review. Firstly, the 
definition of LDCs varied- our definition is similar to 
the World Bank’s term “developing economies,” which 
includes low- and middle-income economies, with gross 
national income (GNI) per capita of less than US$12,616 
(The World Bank 2014a). Discrepancies exist, for exam-
ple, although Russia is categorized as a high income 
country, it is still regarded as a developing country by the 
World Bank, and therefore was included in our analysis. 
Secondly, our review was limited to literature published 
in English, therefore we may have omitted studies pub-
lished in local journals or listed in non-English databases. 
Thirdly, our review does not cover all parameters related 
to launching a MS program, but instead we have selected 
factors which we believe are most important for defining 
a target population, assessing whether a country is well-
equipped, and designing and evaluating the practicality 
of such a program.
Increasing efforts for breast cancer screening have 
been made in LDCs: national recommendations and/or 
guidelines have been laid out, MS programs had been 
incorporated in some countries and relevant studies have 
been conducted in others. Based on our review, there 
may be a role in LDCs to employ western style MS for 
targeted minority groups, such as high socioeconomic 
level and high risk populations. Meanwhile, for LDCs, it 
is also important to ensure patient follow-up to maintain 
high adherence rates, to ensure the accuracy of screen-
ing mammography, to shorten the waiting time to defini-
tive diagnostic procedure after suspicious results, and to 
deliver state-of-the art treatment after early detection 
by screening. MS programs are currently too resource-
demanding for most LDCs, due to the lack of breast 
cancer awareness among the population, the inadequate 
identification of appropriate target populations, the low 
likelihood of up-take and compliance, the scarcity of 
mammography resources, unaffordable screening costs 
and overall sub-optimal outcomes in survival benefit.
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Conclusion
MS is one tool among many to promote early detec-
tion to downstage breast cancer diagnosis and mortality 
reduction. Improving the socioeconomic conditions and 
education level of the population are also methods which 
can drastically increase breast cancer awareness and 
improve the likelihood of improved adherence rates for a 
future MS programs implemented in LDCs. Overall, the 
best interventions for methods for mortality reduction of 
breast cancer must be customized to accommodate local 
conditions, and making the best use of limited resources 
is essential (Fig. 2: flow chart).
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